New consensus guidelines: Genetic testing for prostate cancer patients

New consensus guidelines on genetic testing for prostate cancer (PCa) patients are now available—published in JCO by more than 70 experts from the fields of urology, genetics, and medical oncology.

The guidelines, which provide a framework for genetic evaluation, prostate cancer screening, and management, advise that:

  • hereditary PCa testing should include BRCA1, BRCA2, HOXB13, and DNA mismatch repair genes (EPCAM, PMS2, MSH2, MLH1, and MSH6)
  • a broader subset of PCa patients should receive genetic testing (in addition to metastatic PCa patients)
What does this mean for your practice?

Based on these guidelines, genetic testing may be appropriate for:

  • Men with a family history of cancer on the father’s or mother’s side, including prostate, breast, ovarian, colorectal, pancreatic cancers, and melanoma
  • Men diagnosed with prostate cancer before the age of 55
  • Men with metastatic prostate cancer

 

Invitae offers comprehensive genetic testing for hereditary prostate cancer, as well as extensive support for both you and your patients.

Watch the webinar